By Bridin Murnion

Journal articles

McNeilage AG; Sim A; Nielsen S; Murnion B; Ashton-James CE, 2024, 'Experiences of misuse and symptoms of dependence among people who use gabapentinoids: A qualitative systematic review', International Journal of Drug Policy, 133, http://dx.doi.org/10.1016/j.drugpo.2024.104605

McNamara KA; Murnion B; Fotheringham P; Terplan M; Lintzeris N; Oei JL; Bond DM; Nassar N; Black KI, 2024, 'Interconnections between unintended pregnancy, alcohol and other drug use, and pregnancy, birth, infant, childhood and socioeconomic outcomes: a scoping review', BMJ Sexual and Reproductive Health, 50, pp. 285 - 293, http://dx.doi.org/10.1136/bmjsrh-2023-202140

Langford AV; Bero L; Lin CWC; Blyth FM; Doctor JN; Holliday S; Jeon YH; Moullin JC; Murnion B; Nielsen S; Penm J; Reeve E; Reid S; Wale J; Osman R; Gnjidic D; Schneider CR, 2024, 'Context matters: using an Evidence to Decision (EtD) framework to develop and encourage uptake of opioid deprescribing guideline recommendations at the point-of-care', Journal of Clinical Epidemiology, 165, http://dx.doi.org/10.1016/j.jclinepi.2023.10.020

McNamara KA; Murnion B; Lintzeris N; Chase V; Black E; Malcolm A; Harvey Dodds L; Nassar N; Black KI, 2024, 'Integration of a facilitated access pathway for contraception into alcohol and other drug treatment services: A cohort study comparing metropolitan and regional settings', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13957

McNamara KA; Black K; Bond O; Murnion B; Gordon A; Ludlow J; Nassar N, 2024, 'Planning postpartum contraception for women with substance use disorders: Utilisation of the birth admission', Australian and New Zealand Journal of Obstetrics and Gynaecology, http://dx.doi.org/10.1111/ajo.13887

White CJ; Bailey S; Murnion B; Plit M; Darley D, 2024, 'Acute Tacrolimus Toxicity Due to Paxlovid Successfully Managed with Phenytoin After Lung Transplantation', The Journal of Heart and Lung Transplantation, 43, pp. S480 - S481, http://dx.doi.org/10.1016/j.healun.2024.02.647

Murnion B; Carland JE; Jefferies M; Au M; Tracy M, 2023, '‘It’s a fragile open door’—enhancing COVID-19 vaccination rates in people receiving treatment for substance use disorder', Journal of Public Health (United Kingdom), 45, pp. e729 - e736, http://dx.doi.org/10.1093/pubmed/fdad181

Athavale A; Murnion B, 2023, 'Gabapentinoids: a therapeutic review', Australian Prescriber, 46, pp. 80 - 85, http://dx.doi.org/10.18773/austprescr.2023.025

Chin PKL; Charles K; Murnion B; McGuire TM; Hilmer SN; Martin J; Reith D; Joyce D; Lucas C; Holford N; Day R; Schneider J; Doogue M; Han CH; Herd S; Harrison C; O'Mara D, 2023, 'Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New Zealand', British Journal of Clinical Pharmacology, 89, pp. 3105 - 3115, http://dx.doi.org/10.1111/bcp.15814

McNeilage AG; Nielsen S; Murnion B; Ashton-James C, 2023, 'Experiences of misuse and symptoms of dependence among people who use gabapentinoids: A qualitative systematic review protocol', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2023-073770

Jones CMP; Day RO; Koes BW; Latimer J; Maher CG; McLachlan AJ; Billot L; Shan S; Lin CWC; McLachlan H; Webb M; Hamilton M; Ahedi H; Barber A; Mak W; Mathieson S; Petrova V; Bompoint S; Murnion B; Buckley N; Demirkol A; Wrigley P; Needs C; Brooks L; Cantori S; Preisz P; Aitken J; Allan S; Burke M; Cameron G; Cepeda FJV; Davis C; Dullur J; Emmanuel J; Errey C; Fieuw-Makaroff S; Gaudry A; Genua L; Longhurst I; McCroary K; Merhi D; Nguyen T; Obayd ZR; Penm M; Pobbathi S; Poh WS; Schnitzler P; Shahnaz S; Tan V; Tang D; Tan B; Thu WK; Triantopolous T; Venkatesan R; Wong WCF; Yang SC, 2023, 'Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial', The Lancet, 402, pp. 304 - 312, http://dx.doi.org/10.1016/S0140-6736(23)00404-X

Langford AV; Lin CCW; Bero L; Blyth FM; Doctor J; Holliday S; Jeon YH; Moullin J; Murnion B; Nielsen S; Osman R; Penm J; Reeve E; Reid S; Wale J; Schneider CR; Gnjidic D, 2023, 'Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations', Medical Journal of Australia, 219, pp. 80 - 89, http://dx.doi.org/10.5694/mja2.52002

Jamshidi N; Athavale A; Tremonti C; McDonald C; Banukumar S; Vazquez S; Luquin N; Santiago M; Murnion B, 2023, 'Evaluation of adherence monitoring in buprenorphine treatment: A pilot study using timed drug assays to determine accuracy of testing', British Journal of Clinical Pharmacology, 89, pp. 1938 - 1947, http://dx.doi.org/10.1111/bcp.15318

Lobbe C; Bahnisch J; Lin C; Demirkol A; Murnion B, 2023, 'How do patients and staff in an opioid agonist treatment service view smoking cessation medications and e-cigarettes?', Drug and Alcohol Review, 42, pp. 1092 - 1103, http://dx.doi.org/10.1111/dar.13630

Stojanova J; Carland JE; Murnion B; Seah V; Siderov J; Lemaitre F, 2022, 'Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic', Frontiers in Oncology, 12, http://dx.doi.org/10.3389/fonc.2022.959741

Foran A; Tremonti C; Balgobind V; Sakr H; Murnion B, 2022, 'Transferring patients from high-dose methadone to buprenorphine: A retrospective case series', Journal of Opioid Management, 18, pp. 557 - 566, http://dx.doi.org/10.5055/JOM.2022.0752

Dowla RJ; Stubley C; Murnion B; Cayanan E; Mavros Y; Hardy S; Rooney K, 2022, 'Fitness in recovery: impact of exercise in people with substance use disorder in residential treatment', International Journal of Clinical Trials, 9, pp. 279 - 279, http://dx.doi.org/10.18203/2349-3259.ijct20222688

Nielsen S; Picco L; Murnion B; Winters B; Matheson J; Graham M; Campbell G; Parvaresh L; Khor KE; Betz-Stablein B; Farrell M; Lintzeris N; Le Foll B, 2022, 'Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies', Neuropsychopharmacology, 47, pp. 1315 - 1330, http://dx.doi.org/10.1038/s41386-022-01322-4

Murnion BP; Roberts DM, 2022, 'Responding to the rising number of suicides using barbiturates', Medical Journal of Australia, 216, pp. 187 - 188, http://dx.doi.org/10.5694/mja2.51409

Murnion BP; Demirkol A, 2022, 'Opioid use disorder in anaesthesia and intensive care: Prevention, diagnosis and management', Anaesthesia and Intensive Care, 50, pp. 95 - 107, http://dx.doi.org/10.1177/0310057X211066929

Graham M; Martin JH; Lucas CJ; Murnion B; Schneider J, 2022, 'Cannabidiol drug interaction considerations for prescribers and pharmacists', Expert Review of Clinical Pharmacology, 15, pp. 1383 - 1397, http://dx.doi.org/10.1080/17512433.2022.2142114

Tay E; Lo WKW; Murnion B, 2022, 'Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse', SUBSTANCE ABUSE AND REHABILITATION, 13, pp. 13 - 23, http://dx.doi.org/10.2147/SAR.S315720

Murnion B; Schaffer A; Cairns R; Brett J, 2022, 'Gabapentinoids: repeating mistakes of the past?', Addiction, 117, pp. 2969 - 2971, http://dx.doi.org/10.1111/add.15970

Dowla R; Sinmaz H; Mavros Y; Murnion B; Cayanan E; Rooney K, 2022, 'The Effectiveness of Exercise as an Adjunct Intervention to Improve Quality of Life and Mood in Substance Use Disorder: A Systematic Review', Substance Use and Misuse, 57, pp. 911 - 928, http://dx.doi.org/10.1080/10826084.2022.2052098

Dowla R; Murnion B; Hung C; Currell K; Kendig M; Freeston J; Rooney K, 2021, 'Exercise Capacity and Acute Effect of Exercise on Affect in a Substance Use Disorder Population', Journal of Clinical Exercise Physiology, 10, pp. 142 - 149, http://dx.doi.org/10.31189/2165-6193-10.4.142

Murnion B; Dhaliwal A; Alsop J, 2021, 'Patient characteristics predicting attendance for elective in-patient treatment of substance use disorder', Australasian Psychiatry, 29, pp. 659 - 662, http://dx.doi.org/10.1177/10398562211025034

McCartney D; Isik AD; Rooney K; Arnold JC; Bartlett DJ; Murnion B; Richards E; Arkell TR; Lintzeris N; McGregor IS, 2021, 'The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial', Journal of Sleep Research, 30, http://dx.doi.org/10.1111/jsr.13211

Jamshidi N; Clark D; Murnion B, 2021, 'Recurrent Takotsubo Cardiomyopathy Associated with Opioid Withdrawal During Buprenorphine Induction', Cardiovascular Toxicology, 21, pp. 349 - 353, http://dx.doi.org/10.1007/s12012-020-09624-z

Manandhar P; Murnion BP; Grimsey NL; Connor M; Santiago M, 2021, 'Do gabapentin or pregabalin directly modulate the µ receptor?', PeerJ, 9, http://dx.doi.org/10.7717/peerj.11175

Jamshidi N; Athavale A; Murnion B, 2021, 'Buprenorphine not detected on urine drug screening in supervised treatment', Journal of Opioid Management, 17, pp. 69 - 76, http://dx.doi.org/10.5055/JOM.2021.0644

Cohen M; Murnion B, 2020, 'Does "dependence" on opioids constitute a distinct clinical state?', Pain, 161, pp. 1682 - 1683, http://dx.doi.org/10.1097/j.pain.0000000000001892

Murnion BP; Rivas C; Demirkol A; Hayes V; Lintzeris N; Nielsen S, 2020, 'Acute Experimental Pain Responses in Methadone-and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study', Pain Medicine (United States), 21, pp. 1188 - 1198, http://dx.doi.org/10.1093/pm/pnz178

Athavale A; Murnion B, 2019, 'Unique approach to continuing medical education in clinical pharmacology across Australia and New Zealand', Internal Medicine Journal, 49, pp. 1488 - 1495, http://dx.doi.org/10.1111/imj.14663

Nielsen S; Murnion B; Campbell G; Young H; Hall W, 2019, 'Cannabinoids for the treatment of spasticity', Developmental Medicine and Child Neurology, 61, pp. 631 - 638, http://dx.doi.org/10.1111/dmcn.14165

Cappetta M; Murnion BP, 2019, 'Inpatient management of gamma-hydroxybutyrate withdrawal', Australasian Psychiatry, 27, pp. 284 - 287, http://dx.doi.org/10.1177/1039856218822748

Murnion B; Conigrave KM, 2019, 'Pregabalin misuse: the next wave of prescription medication problems', Medical Journal of Australia, 210, pp. 72 - 73, http://dx.doi.org/10.5694/mja2.12056

Murnion B, 2018, 'Neuropathic pain - definition and drug therapy', AUSTRALIAN PRESCRIBER, 41, pp. 179 - 179, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000451838300003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Nielsen S; Lintzeris N; Murnion B; Degenhardt L; Bruno R; Haber P; Johnson J; Hardy M; Ling S; Saddler C; Dunlop A; Demirkol A; Silsbury C; Phung N; Houseman J; Larance B, 2018, 'Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence', Drug and Alcohol Review, 37, pp. 887 - 896, http://dx.doi.org/10.1111/dar.12859

Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A, 2018, 'Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.', Res Social Adm Pharm, http://dx.doi.org/10.1016/j.sapharm.2018.10.024

Murnion BP, 2018, 'Neuropathic pain: Current definition and review of drug treatment', Australian Prescriber, 41, pp. 60 - 63, http://dx.doi.org/10.18773/austprescr.2018.022

Murnion B, 2018, 'A man using codeine long term for foot pain: Alternative pain management and opioid cessation', Medicine Today, 19, pp. 29 - 30

Cooper S; Campbell G; Larance B; Murnion B; Nielsen S, 2018, 'Perceived stigma and social support in treatment for pharmaceutical opioid dependence', Drug and Alcohol Review, 37, pp. 262 - 272, http://dx.doi.org/10.1111/dar.12601

Stockings E; Campbell G; Hall WD; Nielsen S; Zagic D; Rahman R; Murnion B; Farrell M; Weier M; Degenhardt L, 2018, 'Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: A systematic review and meta-analysis of controlled and observational studies', Pain, 159, pp. 1932 - 1954, http://dx.doi.org/10.1097/j.pain.0000000000001293

Dowla R; Murnion B; Roberts K; Freeston J; Rooney K, 2018, 'Physical activity assessment in clinical studies of substance use disorder', , 1735, pp. 273 - 284, http://dx.doi.org/10.1007/978-1-4939-7614-0_17

Allsop DJ; Rooney K; Arnold JC; Bhardwaj AK; Bruno R; Bartlett DJ; Montebello M; Arkell T; Richards E; Gugusheff J; Rooke S; Kerley W; Murnion B; Haber P; McGregor IS; Lintzeris N, 2017, 'Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol', Mental Health and Physical Activity, 13, pp. 57 - 67, http://dx.doi.org/10.1016/j.mhpa.2017.06.002

Nielsen S; Sabioni P; Trigo JM; Ware MA; Betz-Stablein BD; Murnion B; Lintzeris N; Khor KE; Farrell M; Smith A; Le Foll B, 2017, 'Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis', Neuropsychopharmacology, 42, pp. 1752 - 1765, http://dx.doi.org/10.1038/npp.2017.51

McNamara K, 2016, 'Benzodiazepines', AUSTRALIAN PRESCRIBER, 39, pp. 33 - 33, http://dx.doi.org/10.18773/austprescr.2016.016

Nielsen S; Bruno R; Murnion B; Dunlop A; Degenhardt L; Demirkol A; Muhleisen P; Lintzeris N, 2016, 'Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia', Drug and Alcohol Review, 35, pp. 70 - 75, http://dx.doi.org/10.1111/dar.12315

Murnion B, 2015, 'Medicinal cannabis', Australian Prescriber, 38, pp. 212 - 215, http://dx.doi.org/10.18773/austprescr.2015.072

Nielsen S; Larance B; Lintzeris N; Holliday S; Vanderhaven M; Hordern A; Dunlop A; Haber PS; Murnion B; Silsbury C; Johnson J; Demirkol A; Sadler C; Phung N; Campbell G; Farrell M; Cohen M; Bruno R; Hardy M; Brown A; Houseman J; Degenhardt L, 2015, 'LONGER TERM OUTCOMES FOR PHARMACEUTICAL OPIOID DEPENDENCE: 12 MONTH FINDINGS FROM AN IN-TREATMENT COHORT', DRUG AND ALCOHOL REVIEW, 34, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367694000129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page